This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical study appears to have been conducted on an intention to treat basis. The outcome measures used were: the length of stay (LOS); the mortality rates; admission and discharge diagnoses; the use of diagnostic tests including urinalysis, chest radiograph, blood culture, urine culture, and complete blood count; the duration and use of antibiotics; and the appropriateness of therapy, which was assessed according to current literature and international guidelines.
The study groups were comparable in terms of the demographic and clinical characteristics.
Effectiveness results
The mean LOS was 6.4 (+/-5.9) days (median 5; range: 1 -45) in ward 1 and 5.2 (+/-4.1) days (median 4; range: 1 -30). The difference was statistically significant, (p<0.01).
Crude mortality rates were 6.3%in ward 1 versus 7.9% in ward 2, (p=not significant).
For diagnosis on admission, the patients were more likely to have been classified as having pneumonia in ward 1 than in ward 2 (30% versus 21%; p=0.01), while fever of unknown origin was defined in 34% (ward 1) versus 48% (ward 2) of patients, (p<0.02).
At discharge, there was more uncertainty in the diagnosis in ward 1 than in ward 2 (rate of fever of unknown origin in 24% versus 36%; p00.005). Further, ward 1 patients were significantly more likely to be classified as having a urinary tract infection than ward 2 patients (23% versus 11%; p=0.002) and less likely to be considered as having an upper respiratory tract infection (0% versus 7%, p<0.001).
Diagnostic test usage in ward 1 patients versus ward 2 patients was as follows: urinalysis was performed in 90% versus 67%, (p<0.001); chest radiographs were performed in 96% versus 92%, (p=0.02); blood culture was performed in 92% versus 72%, (p<0.001); urine culture was performed in 92% versus 49%, (p<0.001); complete blood count was performed in 95% in both groups (p non significant); and overall, the five diagnostic tests were performed in 82.5% versus 39% of patients, (p<0.001).
The rates of combination therapy and monotherapy were comparable between the groups. The mean duration of antibiotic therapy was 3.6 (+/-1.5) days (median 3 days; range: 1 -10) in ward 1 and 3.2 (+/-1.5) days (median 3; range: 1 -10) in ward 2, (p non significant). The use of restricted agents was 32% in ward 1 versus 20% in ward 2, (p<0.001). Empirical antibiotic therapy was guided by symptoms in 34% (ward 1) versus 54% (ward 2) of patients, and by anatomy in 66% (ward 1) versus 46% (ward 2) of patients, (p<0.01).
The patients in ward 1 were significantly more likely to receive appropriate therapy than patients in ward 2 (55.5% versus 43%; p=0.012). An alternative agent should have been given for clinical or economic reasons in 36% (ward 1) and 45% (ward 2) of patients, (p=0.06), and for pharmacological reasons in 6.2% (ward 1) versus 8.3% (ward 2) of patients, (p=0.28). No antibiotic therapy was indicated for 1.1% of ward 1 patients versus 3.3% of ward 2 patients, (p=0.16).
Clinical conclusions
The effectiveness analysis showed that the attendance of an IDS led to more appropriate antibiotic usage than nonspecialist attendance. However, significantly higher rates of diagnostic tests and restricted agents were observed in IDStreated patients.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic analysis. In effect, a cost-consequences analysis was carried out.
Direct costs
Discounting was not relevant since the costs per patient were incurred during a short timeframe. The unit costs were not presented separately from the quantities of resources used. Only the costs of antibiotic therapy were considered in the analysis. The costs of vial preparation and personnel costs were not considered. The cost/resource boundary of the hospital appears to have been adopted. The estimation of resource use was presumably based on the quantities of antibiotics used in the sample of patients included in the clinical trial. The source of the costs was not explicitly reported, but it could have been the final department of the study hospital. The price year was not reported.
